Skip to main content

What the FDA labels say about taking them together

Atovaquone and efavirenz

Efavirenz's FDA label of March 31, 2024 names atovaquone in its drug interactions section; the atovaquone label PlainMeds reads does not name efavirenz. The efavirenz label: “Consider alternatives to artemether/ lumefantrine because of the risk of QT interval prolongation. Concomitant administration is not recommended.”

Check it at the source: the atovaquone FDA label on DailyMed (effective March 20, 2026); the efavirenz FDA label on DailyMed (effective March 31, 2024, Cipla USA Inc.).

What does the atovaquone label say about efavirenz?

Atovaquone's label (effective March 20, 2026) does not name efavirenz in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (MEPRON), GlaxoSmithKline LLC, effective March 20, 2026 (SPL set b426b6bf-f07e-4580-97ae-dfca1ddf5b8f), via openFDA; the full label on DailyMed

What does the efavirenz label say about atovaquone?

Efavirenz label, drug interactions

Concomitant Drug Class/Drug Name: Antimalarials: Artemether/lumefantrine Atovaquone/ proguanil; Effect: ↓ artemether * ↓ dihydroartemisinin * ↓ lumefantrine * ↓ atovaquone ↓ proguanil; Clinical Comment: Consider alternatives to artemether/ lumefantrine because of the risk of QT interval prolongation. Concomitant administration is not recommended.

Source: FDA drug label (Efavirenz), Cipla USA Inc., effective March 31, 2024 (SPL set 92603fa5-7a2c-4bfb-9a70-aadb4fba952c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

20Atovaquone generic labelers
5Efavirenz generic labelers
AtovaquoneEfavirenz
Labeled forn/aHIV
Boxed warningNoNo
Pharmacy cost (NADAC)$0.767 per mL 750 mg/5 mL suspension$1.28 per tablet 600 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?